St. Jude Reference #SJ-05-0002
Methods are provided for modulating the activity of p53 tumor suppressor protein by affecting p53 translational regulation. The methods involve affecting the function of a p53 5’-untranslated region (5’UTR), including its interaction with proteins such as Ribosomal Protein L26 (RPL26), nucleolin, and p53. Use of RPL26 siRNA to downregulate p53 induction is shown. These methods can be developed for treatment of cancer, neurodegenerative disorders and minimizing the negative effects of cellular stresses.
p53, nucleolin, RPL26
Granted patents or published applications
Patent issued as US 8,933,043
Related scientific references
Chen, J. et al., “Interactions of nucleolin and ribosomal protein L26 (RPL26) in the translational control of human p53”, J. Biol. Chem. (Epub. Mar. 20, 2012);
Takagi, M. et al., “Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin”, Cell 123: 49-63 (Oct. 6, 2005).
We are currently seeking licensing opportunities in all fields for the development of this technology. Contact: firstname.lastname@example.org
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.